---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006349"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:49:56.312475+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IDEAYA reports cash $373.1M, net loss $58.7M; darovasertib data mid-2023

## Summary
- Cash, cash equivalents and marketable securities $373.1M as of Dec 31, 2022; sufficient to fund operations into 2026.
- Net loss $58.7M for FY2022 vs $49.8M in FY2021; Q4 collaboration revenue $4.0M vs $3.0M.
- Targeting mid-2023 clinical efficacy update for darovasertib/crizotinib in ~20 first-line MUM patients; goals: >20% ORR, >5 months mPFS.
- First-patient dosing of IDE161 (PARG) in Q1 2023; IND submission for Pol Theta Helicase in Q2 2023 with GSK.
- Discontinuing IDE397+chemo cohorts; prioritizing IDE397/AMG193 combination with Amgen.

## SEC filing metadata
- accession: 0000950170-23-006349
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017023006349/0000950170-23-006349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017023006349/idya-20230307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006349
- JSON: https://secwatch.observer/filing/0000950170-23-006349.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006349.txt

## Key facts
- Earnings Releases
  IDEAYA Biosciences, Inc. reported financial results for year ended December 31, 2022.
  - Period: year ended December 31, 2022
  - Result: reported results
  source text: On March 7, 2023, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1676725/000095017023006349/0000950170-23-006349-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.